1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

Summary

Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

The 2013 base-year market sales of asthma products in France were $918m.The relatively slow growth of the German market compared with the French, Spanish, and UK markets is attributable to the slightly decreasing prevalence of asthma in this country over the forecast period. . Advair’s active patent on the Diskus delivery platform in Italy has already expired, but still generates high sales numbers due to the difficulties involved in replicating the delivery technology. GlobalData believes that Advair will slowly lose its dominant position in the Spanish market. GlobalData expects Breo Ellipta to dominate the branded segment of the UK ICS/LABA market, as it is the first complete regimen to be dosed once daily for asthma treatment.

Scope

- Overview of Asthma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU (the UK, France, Italy, Spain, Germany) from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Asthma market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of drug performance.
- Obtain sales forecast for drugs from 2013-2023 in 5EU (the UK, France, Italy, Spain, Germany).

Table Of Contents

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 16
2.1 Catalyst 16
2.2 Related Reports 16
2.3 Upcoming Related Reports 18
3 Disease Overview 19
3.1 Etiology and Pathophysiology 19
3.1.1 Etiology 19
3.1.2 Pathophysiology 21
3.1.3 Prognosis 23
3.1.4 Quality of Life 23
3.2 Symptoms 24
4 Disease Management 25
4.1 Diagnosis and Treatment Overview 25
4.1.1 Diagnosis 25
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs 26
4.1.3 Clinical Practice 28
4.2 France 32
4.3 Germany 34
4.4 Spain 36
4.5 Italy 38
4.6 UK 40
5 Competitive Assessment 42
5.1 Overview 42
5.2 Strategic Competitor Assessment 44
5.3 Inhaled Corticosteroids 48
5.3.1 Flovent (fluticasone propionate) 48
5.3.2 Pulmicort (budenoside) 52
5.3.3 Other Inhaled Corticosteroids 56
5.4 Long-Acting Beta-Agonists 57
5.4.1 Overview 57
5.5 Inhaled Corticosteroids/Long-Acting Beta-Agonists 58
5.5.1 Advair (fluticasone propionate/salmeterol xinafoate) 58
5.5.2 Symbicort (budenoside/formoterol fumarate) 64
5.5.3 Breo Ellipta (fluticasone furoate/vilanterol trifenatate) 67
5.5.4 Flutiform (fluticasone propionate/formoterol fumarate) 71
5.5.5 Fostair (beclomethasone dipropionate/formoterol fumarate) 75
5.6 Leukotriene Modifiers 79
5.6.1 Singulair (montelukast) 79
5.6.2 Other Leukotriene Modifiers 83
5.7 Short-Acting Beta-Agonists 84
5.7.1 Overview 84
5.7.2 Efficacy 85
5.7.3 Safety 86
5.8 Targeted Therapies 87
5.8.1 Xolair (omalizumab) 87
5.9 Anticholinergics 90
5.9.1 Spiriva (tiotropium bromide) 90
6 Unmet Need and Opportunity 95
6.1 Overview 95
6.2 Personalized Therapies to Control Severe Asthma 96
6.2.1 Unmet Need 96
6.2.2 Gap Analysis 97
6.2.3 Opportunity 97
6.3 Better Patient Compliance 97
6.3.1 Unmet Need 97
6.3.2 Gap Analysis 98
6.3.3 Opportunity 99
6.4 Lower Cost of Asthma Medications 99
6.4.1 Unmet Need 99
6.4.2 Gap Analysis 100
6.4.3 Opportunity 100
6.5 Proper Diagnosis of Asthma in Children 100
6.5.1 Unmet Need 100
6.5.2 Gap Analysis 101
6.5.3 Opportunity 101
7 Pipeline Assessment 102
7.1 Overview 102
7.2 Promising Drugs in Clinical Development 104
7.2.1 Fluticasone furoate 105
7.2.2 Cinquil (reslizumab) 109
7.2.3 Bosatria (mepolizumab) 114
7.2.4 Lebrikizumab 119
7.2.5 Benralizumab 124
7.2.6 Dupilumab 129
7.2.7 Quilizumab 135
7.2.8 Tralokinumab 139
8 Market Outlook 144
8.1 Global 144
8.1.1 Drivers and Barriers - Global Issues 144
8.2 France 146
8.2.1 Forecast 146
8.2.2 Key Events 151
8.2.3 Drivers and Barriers 151
8.3 Germany 154
8.3.1 Forecast 154
8.3.2 Key Events 159
8.3.3 Drivers and Barriers 160
8.4 Italy 162
8.4.1 Forecast 162
8.4.2 Key Events 167
8.4.3 Drivers and Barriers 167
8.5 Spain 169
8.5.1 Forecast 169
8.5.2 Key Events 175
8.5.3 Drivers and Barriers 176
8.6 United Kingdom 178
8.6.1 Forecast 178
8.6.2 Key Events 183
8.6.3 Drivers and Barriers 184
9 Appendix 186
9.1 Bibliography 186
9.2 Abbreviations 196
9.3 Methodology 201
9.4 Forecasting Methodology 201
9.4.1 Diagnosed Asthma Patients 201
9.4.2 Percent Drug-Treated Patients 202
9.4.3 Drugs Included in Each Therapeutic Class 202
9.4.4 Key Launch and Patent Expiry Dates 203
9.4.5 General Pricing Assumptions 203
9.4.6 Individual Drug Assumptions 204
9.4.7 Generic Erosion 210
9.4.8 Pricing of Pipeline Agents 210
9.5 Physicians and Specialists Included in This Study 212
9.6 About the Authors 215
9.6.1 Author 215
9.6.2 Author/Reviewer 215
9.6.3 Reviewer 216
9.6.4 Global Head of Healthcare 216
9.7 About GlobalData 217
9.8 Disclaimer 217

1.1 List of Tables

Table 1: Symptoms of Asthma 24
Table 2: Treatment Guidelines for Asthma by Country 26
Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013 27
Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency 30
Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age 32
Table 6: Country Profile - Asthma Management, France 33
Table 7: Country Profile, Asthma Management - Germany 35
Table 8: Country Profile, Asthma Management - Spain 37
Table 9: Country Profile, Asthma Management - Italy 39
Table 10: Country Profile, Asthma Management - UK 41
Table 11: Leading Treatments for Asthma, 2014 47
Table 12: Product Profile - Flovent 49
Table 13: Efficacy - Flovent Diskus Versus Placebo 50
Table 14: Adverse Events Related to Flovent Diskus 51
Table 15: Flovent SWOT Analysis, 2014 51
Table 16: Product Profile - Pulmicort 53
Table 17: Pulmicort-Associated Adverse Events 55
Table 18: Pulmicort SWOT Analysis, 2014 56
Table 19: Summary of Other Marketed ICSs for Asthma Treatment, 2014 57
Table 20: Product Profile - Advair 61
Table 21: Efficacy - Advair Diskus Versus Its Individual Components 62
Table 22: Advair, Frequency of Drug-Related Adverse Events 62
Table 23: Advair SWOT Analysis, 2014 63
Table 24: Product Profile - Symbicort 65
Table 25: Efficacy - Symbicort Versus Its Individual Components 66
Table 26: Symbicort, Frequency of Drug-Related Adverse Events 66
Table 27: Symbicort SWOT Analysis, 2014 67
Table 28: Product Profile - Breo Ellipta 69
Table 29: Efficacy - Breo Ellipta Versus Flovent 70
Table 30: Safety - Breo Ellipta Versus Flovent 70
Table 31: Breo Ellipta SWOT Analysis, 2014 71
Table 32: Product Profile - Flutiform 73
Table 33: Efficacy - Flutiform Versus Advair 74
Table 34: Safety - Flutiform Versus Advair 74
Table 35: Flutiform SWOT Analysis, 2014 75
Table 36: Product Profile - Fostair 77
Table 37: Efficacy - Fostair Versus Symbicort 78
Table 38: Safety - Fostair Versus Symbicort 78
Table 39: Fostair SWOT Analysis, 2014 79
Table 40: Product Profile - Singulair 81
Table 41: Efficacy - Singulair+Pulmicort Versus Double-Dose of Pulmicort 82
Table 42: Safety of Singulair+Pulmicort Compared With a Double Dose of Pulmicort 82
Table 43: Singulair SWOT Analysis, 2014 83
Table 44: Overview of the Leading SABAs for Asthma Treatment, 2014 85
Table 45: Efficacy - Nebulized Levalbuterol Versus Nebulized Albuterol 86
Table 46: Adverse Events Related to Nebulized Levalbuterol and Nebulized Albuterol 86
Table 47: Product Profile - Xolair 88
Table 48: Efficacy - Xolair Versus Placebo 89
Table 49: Xolair SWOT Analysis, 2014 90
Table 50: Product Profile - Spiriva 92
Table 51: Efficacy - Spiriva's Versus LABA and Double-Dose ICS 93
Table 52: Adverse Events Related to the Use of Spiriva 93
Table 53: Spiriva SWOT Analysis, 2014 94
Table 54: Unmet Need and Opportunity in Asthma 95
Table 55: Asthma - Late Stage Pipeline, 2014 104
Table 56: Product Profile - Fluticasone Furoate 106
Table 57: Fluticasone Fuorate Efficacy Versus Placebo and Fluticasone Propionate 107
Table 58: Fluticasone Furoate Safety Profile 107
Table 59: Fluticasone Furoate SWOT Analysis, 2014 109
Table 60: Product Profile - Cinquil 110
Table 61: Efficacy of Cinquil Versus Placebo 111
Table 62: Cinquil's Safety Profile 112
Table 63: Cinquil SWOT Analysis, 2014 114
Table 64: Product Profile - Bosatria 116
Table 65: Efficacy of Bosatria Versus Placebo 116
Table 66: Bosatria's Safety Profile 117
Table 67: Bosatria SWOT Analysis, 2012 119
Table 68: Product Profile - Lebrikizumab 121
Table 69: Efficacy of Lebrikizumab Versus Placebo 121
Table 70: Lebrikizumab Safety Profile 122
Table 71: Lebrikizumab SWOT Analysis, 2014 124
Table 72: Product Profile - Benralizumab 126
Table 73: Efficacy of Benralizumab Versus Placebo 127
Table 74: Benralizumab SWOT Analysis, 2014 129
Table 75: Product Profile - Dupilumab 131
Table 76: Efficacy of Dupilumab Versus Placebo 132
Table 77: Dupilumab's Safety Profile 132
Table 78: Dupilumab SWOT Analysis, 2014 134
Table 79: Product Profile - Quilizumab 136
Table 80: Efficacy of Quilizumab Versus Placebo 136
Table 81: Quilizumab SWOT Analysis, 2014 139
Table 82: Product Profile - Tralokinumab 140
Table 83: Efficacy of Tralokinumab Versus Placebo 141
Table 84: Tralokinumab's Safety Profile 141
Table 85: Tralokinumab SWOT Analysis, 2014 143
Table 86: Global Asthma Market - Drivers and Barriers, 2014 144
Table 87: Sales Forecast ($m) for Asthma in France, 2013-2023 148
Table 88: Key Events Impacting Sales for Asthma in France, 2013-2023 151
Table 89: French Asthma Market - Drivers and Barriers, 2013-2023 151
Table 90: Sales Forecast ($m) for Asthma in Germany, 2013-2023 156
Table 91: Key Events Impacting Sales for Asthma in Germany, 2013-2023 159
Table 92: Asthma Market - Drivers and Barriers in Germany, 2013-2023 160
Table 93: Sales Forecasts ($m) for Asthma in Italy, 2013-2023 164
Table 94: Key Events Impacting Sales for Asthma in Italy, 2013-2023 167
Table 95: Asthma Market - Drivers and Barriers in Italy, 2013-2023 167
Table 96: Sales Forecast ($m) for Asthma in Spain, 2013-2023 172
Table 97: Key Events Impacting Sales for Asthma in Spain, 2013-2023 175
Table 98: Asthma Market - Drivers and Barriers in Spain, 2013-2023 176
Table 99: Sales Forecast ($m) for Asthma in the UK, 2013-2023 180
Table 100: Key Events Impacting Sales for Asthma in the UK, 2013-2023 183
Table 101: Asthma Market - Drivers and Barriers in the UK, 2013-2023 184
Table 102: Key Launch Dates 203
Table 103: Key Patent Expiries 203
Table 104: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 214

1.2 List of Figures
Figure 1:Stepwise Disease Management Approach for Asthma in Adults 28
Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger 31
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023 105
Figure 4: Sales for Asthma in France by Drug Class, 2013-2023 150
Figure 5: Sales for Asthma in Germany by Drug Class, 2013-2023 158
Figure 6: Sales for Asthma in Italy by Drug Class, 2013-2023 166
Figure 7: Sales for Asthma in Spain by Drug Class, 2013-2023 174
Figure 8: Sales for Asthma in the United Kingdom by Drug Class, 2013-2023 182

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Medical Affairs Reputations: Asthma/COPD (US)

Medical Affairs Reputations: Asthma/COPD (US)

  • $ 5390
  • Industry report
  • October 2016
  • by Firstword Pharma

Which medical affairs team is losing out despite high performance and satisfaction scores? Compare the medical affairs teams for 12 major Asthma/COPD drugs head to head. Find out which three teams are ...

Medical Affairs Reputations: Asthma/COPD (EU)

Medical Affairs Reputations: Asthma/COPD (EU)

  • $ 5390
  • Industry report
  • October 2016
  • by Firstword Pharma

Close races for 1st and 2nd place medical affairs team. Where does your team rank? Compare the medical affairs teams for 12 major Asthma/COPD drugs head to head. Find out which two teams are neck and ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.